Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
Price : $35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2022.
- 12 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2022.